rose in Biological Technology

Sanford Rose Associates Opens Minneapolis Office

MINNETONKA, Minn., July 17 /PRNewswire/ -- John H. Wang has been named Managing Director of Sanford Rose Associates - Minneapolis, one of several new Sanford Rose Associates executive search offices opening in recent months. Most recently, John served as Chief Technology Officer at CircuLite,...

AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R)

CENTENNIAL, Colo., Dec. 29 /PRNewswire/ -- AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures, will this year sponsor one of the 26 float riders aboard the annual Donate Life float in the January 1 Tournament of Rose...

Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board

NEW YORK, Dec. 20 /PRNewswire/ -- MacAndrews & Forbes Holdings Inc. announced today that Dr. Eric Rose, its Executive Vice President for Life Sciences, who also serves as Chief Executive Officer of SIGA Technologies, Inc., has been named to the National Biodefense Science Board (NBSB). The NBS...

Prix Galien USA Announces 2009 Final Candidates

...ular disease and diabetes and treatments for people living with cancer and HIV/AIDS. The 2009 Prix Galien USA ceremony will again be emceed by Charlie rose at the American Museum of Natural History in New York. Final candidates for the Prix Galien USA 2009 awards are: Best Pharmaceutical ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

...e HPV test, including partnering. Corporate Updates Senior Management Update - The company is pleased to report the addition of Mary rose Keller to the senior management team, as vice president of clinical operations. Ms. Keller brings more than 25 years of clinical research experience a...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...une 30, 2009 of $4.9 million (2008: $nil). US oral mesalamine market share Shire's average market share of the US oral mesalamine market rose to 31.8% for the three months to June 30, 2009 (2008: 27.6%). LIALDA/MEZAVANT - Ulcerative colitis Product sales of LIALDA/MEZAVANT for ...

Sanofi-aventis Announces Second Quarter 2009 Results

...articular the consolidation of Zentiva), net sales rose by 6.5%. Excluding changes in structure and at con... North America effective April 1, 2008), net sales rose by 3.1%. Excluding changes in structure and at con...Lantus ((R)) , the world's leading insulin brand, rose by 26% in the second quarter (to euro 792 million)...

China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results

...t sales increased 18.9% year-over-year to $15.5 million -- Gross profit rose 21.0% to $10.6 million, with a gross margin of 68.5% -- Net income was ...ights -- Net sales increased 28.1% to $54.2 million -- Gross profit rose 26.6% to $38.0 million, with a gross margin of 70.1% -- Operating incom...

Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry

...orked at La Jolla Pharmaceutical Company, an R&D based biotech company in San Diego, USA for 12 years. At La Jolla Pharmaceutical Company, Dr. Xu rose through the ranks from Research Scientist, to Manager, Senior Manager, and Associate Director of Process Development. Through this career path, he acc...

DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research

...t DNA saliva samples on-site at the Susan G. Komen Western New York Race for the Cure®. The race will be held this June 13th at the Delaware Park rose Gardens in Buffalo, NY. This event is the second of its kind under the "Spit for the Cure"™ umbrella and joins the very successfu...

The MedZilla Report: April 2009 Employment Outlook for Biotech/Pharma/Health

... Despite announcements of layoffs in the healthcare field, job growth rose slightly, with 17,000 more jobs created in April. Though there was an increase of more than 20 percent from March, job growth overall is off by about ...

DFG establishes 14 new research training groups

...re also to be combined with language- and country-related regional science. For this purpose, the group is working in close cooperation with the White rose East Asia Centre of the universities of Leeds and Sheffield. (Host university: University of Duisburg-Essen; Spokesperson: Professor Dr. Karen A. Shir...

China Biologic Products Announces Strong First Quarter 2009 Results

...ncrease in the cost of raw materials associated with the increased compensation fee for donors. Operating expenses in the first quarter of 2009 rose 115.3% to $4.9 million. Selling expenses increased 17.2% to $0.6 million. As a percentage of sales, selling expenses in the first quarter of 2009 was...

China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results

...perations increased by 140% to $1.6 million in the third quarter of 2009, compared to $0.7 million in the prior year quarter; -- Net income rose over 200% to $1.3 million in the third quarter of 2009, or $0.04 per diluted share, compared with $0.4 million, or $0.01 per share in th...

Tiens Biotech Group (USA) Reports First Quarter Results

...for the first quarter of 2008, reflecting a significant increase in international sales. Net income attributable to the Company for the quarter rose 138.1% to $8.6 million, or $0.12 per share, compared to net income of $3.6 million, or $0.05 per share, for the 2008 first quarter. For the fir...

ThromboGenics NV: Business Update

...rporate Update ThromboGenics has continued to strengthen the Company with a number of strategic hires in the R&D and regulatory areas. Lene rose Arfelt has recently joined ThromboGenics in the new position of Head of Global Quality and European Regulatory Affairs. This position has been created...

Shire begins the year with a strong performance

...amine market share Driven by the growth of LIALDA since its launch in March 2007, Shire's average market share of the US oral mesalamine market rose to 31.1% for the three months to March 31, 2009 (2008: 26.1%). LIALDA/MEZAVANT - Ulcerative colitis Product sales of LIALDA/MEZAVANT for...

China Biologic Products Announces Strong 2008 Results

...the increase in selling prices, as well as management's ability to maintain efficiencies in the production process. Operating expenses for 2008 rose 27.6% to $12.4 million and selling expenses decreased 50.1% to $2.2 million. The substantial decrease in selling expense reflects the normalization of...

Neogen Reports Record Third Quarter

...ed 11% to $27,840,000, a record third quarter for the 26-year-old company, compared to the prior year's $25,180,000. Year-to-date, nine-month revenues rose 17% in the current fiscal year to $87,831,000 from FY 2008's $75,299,000. Year-to-date net income for the first nine months of Neogen's 2009 ...

ERT Reports Fourth Quarter and Full Year 2008 Results

... 2008. For 2008, new bookings were a record $187.2 million, up 35.1% from $138.6 million in 2007. The percent of new bookings in Phase III/IV rose to 59.4%, up from 44.4% in the prior year's fourth quarter. Backlog increased to $166.5 million as of December 31, 2008, an increase of 18.8% ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

...iod in 2007 (2007: $66.8 million). On a constant exchange rate basis, sales rose 15% (XAGRID is primarily sold in Euros and Pounds sterling). DYNEPO ... sales in Europe and Asia Pacific. On a constant exchange rate basis, sales rose by 19%. FIRAZYR - HAE During the second half of 2008 FIRAZYR ...

Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US

...tion and information services. We see the most significant value increase in the US, where the percent of GPs rating physician education as important rose from 66% in 2008 to 71% in 2009. More than 70% of physicians in the UK and France and more than 80% in Germany, Spain and Italy also place high value...

Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009

...reased its sales by 10.7% (12.8% on a like-for-like exchange-rate basis) and thereby passed the billion euro mark. Operating results (Adjusted EBITDA) rose by 13.7% to EUR206.4m (prior year: EUR181.6m). The Adjusted EBITDA margin reached 19.5% in 2008 (prior year: 19%). There was a substantial improvement...

Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results

...cond quarter 2009 revenues were $14.80 million, as compared to $24.95 million reported in the second quarter of fiscal 2008. Sales of glucose products rose to $9.25 million during the second quarter, representing 62.5% of revenues and 12.7% quarter-over-quarter growth. Cornstarch sales for the quarter tot...

Neogen Reports Best Quarter in Its 26-Year History

...ious year's second quarter. On a per-share basis, net income in the quarter rose to $0.26, compared to the prior year's $0.22. Neogen's second quarter net i...rly record, compared to the prior year's $27,210,000. Year-to-date revenues rose 20% during the fiscal year's first half to $59,992,000 from FY 2008's $50,1...

Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors

...esident and General Manager for the worldwide Diagnostic Business Group. Prior to that, Dr. Stoll worked for American Hospital Supply Corp., where he rose from Director of Clinical Pharmacology to President of the American Critical Care Division. He began his pharmaceutical career at the Upjohn Company,...

Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer

... in the world last year, Pravachol(R) and Avapro(R). Ms. McDonald began her career in the pharmaceutical industry at Johnson & Johnson, where she rose to the leadership of the company's largest pharmaceutical franchise as Vice President, Oncology at Ortho Biotech. Ms. McDonald is a Director ...

The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance

...increased 50% to $10.7 million, or 41.9% of net revenues, in FY2008, compared with $7.2 million, or 37.0% of net revenues, in FY2007. Operating income rose to $3.2 million, a 252% improvement from $0.9 million in FY2007. In FY2008, the Company sold 34.7 million female condoms, an increase of 34% over the ...

Sinovac Reports Third Quarter 2008 Unaudited Financial Results

...d September 30, 2008. Highlights -- Sales year-to-date increased 40% year-over-year to $34.1 million -- Operating income year-to-date rose 22.5% year-over-year to $12.4 million -- Net income year-to-date maintained at same level year-over-year at $5.6 million, inclusive ...

Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe

...'s first year, 238 undergraduate students were selected as Amgen Scholars from approximately 1,700 applicants from across the U.S. In 2008, applicants rose to nearly 2,400 and nearly 250 students, representing 120 different U.S. colleges and universities, were chosen to participate. The opportunity to w...

The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health

...market for new employees. Posted jobs for new medical education specialists rose by more than ten percent, followed by postings for medical and surgical candidates at 5.7 percent. Even sales representative postings rose from August to September by almost two percent. Less likely to be seen were...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

...cross its business. Product sales were up 31% and Non GAAP earnings per ADS rose 88%, compared with the same period last year. "Our new products continued... market share Shire's average quarterly market share of the US ADHD market rose to 32.9% in the three months to September 30, 2008 (2007: 29.7%), driven by...

High-quality DNA/RNA from Microorganisms in Environmental Samples

...that they routinely encounter high levels of PCR inhibiton in nucleic acids isolated from environmental samples. I am very pleased that our scientists rose to the challenge and designed high quality kits that purify nucleic acids free of PCR inhibitors. We are confident that microbiologists will be satisf...

Gerresheimer Substantially Increases Quarterly Operating Profit

...ge-rate basis, to EUR77.6 m (prior year: EUR68.1m). The main growth generator in this Division was RTF (Ready-to-Fill) syringe systems, sales of which rose by 54%. Production capacity for RTF syringes is now fully utilised. In order to cover the sustained high level of demand, a substantial investment is ...

Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets

...e were completed in the first half of 2008. Total 2007 funding through IPOs rose to US$1.1 billion, a 54% increase over 2006. The average valuation at the t...sed by 6% in 2007 from the previous year, to US$111 billion, and net income rose by 2%. Total revenue for all publicly traded medtech companies in the US, i...

tootoo.com: China's Farmers Welcome the New Trend of Organic Farming

...cerns over potentially contaminated produce. According to the Agriculture Ministry of China, in 2007, the domestic consumption value of organic food rose to 38 billion US dollars, while the export value was over 3 billion US dollars. Chinese farmers produced 20,000 kinds of organic food, or around 1440 ...

Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results

... United States, sales increased by 15.1% to $5,765,000. Sales in Europe increased by 10.5% to $1,727,000 and sales in the Asia-Pacific region rose considerably by 727% to $1,788,000. - The Company substantially increased its productions, generating growth of 54% in sales volume, which is, how...

Essilor's First-Half 2008 Results

...riable-tint lenses in North America. Profit attributable to equity holders of the parent was 9.0% higher, at EUR198.3 million. Earnings per share rose by 8.1% to EUR0.96. Inventories and work in progress Inventories amounted to EUR400 million at June 30, 2008, compared with 394 million at Decembe...

Yongye Biotechnology International Announces Second Quarter Results

...rk. Gross profit was $9.6 million in the second quarter of 2008, an increase of 171.8% from $3.5 million in the second quarter of 2007. Gross margin rose to 54.6% from 47.5% in the second quarter of 2007. Gross margin increased because of cost efficiencies resulting from increased production and more st...

Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results

... reflecting successful marketing efforts in China and the increase in the value of the renminbi against the dollar. In addition, international revenue rose 21.4% to $11.1 million for the second quarter, compared to $9.2 million for the same period in 2007, reflecting a reduction on export restrictions in ...